BioNexus Gene Lab Corp
corporate_fare Company Profile
BioNexus Gene Lab Corp (NASDAQ:BGLC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors BGLC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- BioNexus Gene Lab Corp's Q1 Revenue Crashes 99% to $22.84K, Deepening Going Concern Worries
- BioNexus Gene Lab Reports 98.9% Revenue Collapse, Ongoing Going Concern Doubt, and Sues Former Officers for $2.9M
- Annual Report Reveals Going Concern Doubt, Material Weakness, and Significant Dilution Risks
- BioNexus Gene Lab Corp.'s Strategic Partner Fidelion Diagnostics Appoints Dr. Muthu Meyyappan as Chief Commercial Officer
- BioNexus Gene Lab Completes Subsidiary Governance Restructuring, Appoints New Chairman
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for BGLC, detected from its recent SEC filings · based on capital-structure filings through 2026-04-14.
Going Concern Warning Issued · Material Weakness in Internal Controls
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →